Skip to Content

Certolizumab Dosage

Applies to the following strength(s): 200 mg ; 200 mg/mL

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for Rheumatoid Arthritis

Initial dose: 400 mg subcutaneously (given as two subcutaneous injections of 200 mg) at weeks 0, 2, and 4, followed by 200 mg subcutaneously every other week
Maintenance dose: 400 mg subcutaneously every 4 weeks in patients who obtain a clinical response

Comments:
-Injection sites should be rotated and injections should not be given in areas where the skin is tender, bruised, red, or hard. When a 400 mg dose is needed (given as 2 subcutaneous injections of 200 mg), injections should occur at separate sites in the thigh or abdomen.

Use: For treatment of adults with moderately to severely active rheumatoid arthritis (RA)

Usual Adult Dose for Psoriatic Arthritis

Initial dose: 400 mg subcutaneously (given as two subcutaneous injections of 200 mg) at weeks 0, 2, and 4, followed by 200 mg subcutaneously every other week
Maintenance dose: 400 mg subcutaneously every 4 weeks in patients who obtain a clinical response

Comments:
-Injection sites should be rotated and injections should not be given in areas where the skin is tender, bruised, red, or hard. When a 400 mg dose is needed (given as 2 subcutaneous injections of 200 mg), injections should occur at separate sites in the thigh or abdomen.
-This drug can be given as monotherapy in case of intolerance to methotrexate (MTX) or when continued treatment with methotrexate is inappropriate.
-MTX should be continued during treatment with this drug where appropriate.
-Injection sites should be rotated and injections should not be given in areas where the skin is tender, bruised, red, or hard. When a 400 mg dose is needed (given as 2 subcutaneous injections of 200 mg), injections should occur at separate sites in the thigh or abdomen.

Use: For the treatment of adult patients with active psoriatic arthritis (PsA)

Usual Adult Dose for Ankylosing Spondylitis

Initial dose: 400 mg subcutaneously (given as two subcutaneous injections of 200 mg) at weeks 0, 2, and 4, followed by 200 mg subcutaneously every 2 weeks or 400 mg subcutaneously every 4 weeks

Comments:
-Injection sites should be rotated and injections should not be given in areas where the skin is tender, bruised, red, or hard. When a 400 mg dose is needed (given as 2 subcutaneous injections of 200 mg), injections should occur at separate sites in the thigh or abdomen.

Use: For the treatment of adults with active ankylosing spondylitis

Usual Adult Dose for Crohn's Disease - Maintenance

Initial dose: 400 mg subcutaneously (given as two subcutaneous injections of 200 mg) at weeks 0, 2, and 4
Maintenance dose: 400 mg subcutaneously every 4 weeks in patients who obtain a clinical response

Comments:
-Injection sites should be rotated and injections should not be given in areas where the skin is tender, bruised, red, or hard. When a 400 mg dose is needed (given as 2 subcutaneous injections of 200 mg), injections should occur at separate sites in the thigh or abdomen.

Use: For reducing signs of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

US BOXED WARNINGS:
-SERIOUS INFECTIONS: Use of this drug increases the risk of serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens. If a patient develops a serious infection or sepsis this drug should be discontinued. A test for latent TB should be performed; if positive, treatment for TB should be started prior to starting therapy with this drug.
All patients should be monitored for active TB during treatment, even if the initial latent TB test was negative.
-LYMPHOMA AND OTHER MALIGNANCIES: Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers. This drug is not indicated for use in pediatric patients.

Pediatric statement: Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-For subcutaneous administration only.
-Suitable administration sites include the abdomen or thigh.
-The patient may self-inject only if the physician determines that it is appropriate, training in proper technique has been provided, and with appropriate medical follow-up as necessary.
-For a 400 mg dose, this drug should be administered as 2 subcutaneous injections of 200 mg each on the same day.

Storage requirements:
-Store in refrigerator at 2C to 8C ; do not freeze.
-Keep in outer carton to protect from light.

Patient advice:
-Dizziness (including vertigo, vision disorder, and fatigue) have been reported following administration of this drug.

Hide